Key result
In a canine model of hypothermic ventricular fibrillation, neither amiodarone (10%) nor bretylium (40%) significantly improved return of spontaneous circulation versus placebo (30%, p=0.45).
Why the study?
Does amiodarone or bretylium improve resuscitation rates compared to placebo in a canine model of hypothermic ventricular fibrillation?
RCT (n=30)
blinded
randomized
Does amiodarone or bretylium improve resuscitation rates compared to placebo in a canine model of hypothermic ventricular fibrillation?
Absolute Event Rate: 10% vs 30%
p-value: p=0.45
In a canine model of severe hypothermic ventricular fibrillation, neither amiodarone nor bretylium significantly improved resuscitation rates compared to placebo.
No takes yet. Share an insight, caveat, or question.
Neither agent improved ROSC in this canine model; leaves open any role for antiarrhythmics in human hypothermic VF.
Stoner et al. (2003) conducted an RCT in Severe hypothermic ventricular fibrillation (n=30). Amiodarone or Bretylium vs. Placebo was evaluated on Return of spontaneous circulation (ROSC) (p=0.45). In a canine model of hypothermic ventricular fibrillation, neither amiodarone (10%) nor bretylium (40%) significantly improved return of spontaneous circulation versus placebo (30%, p=0.45).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: